L
Lorenzo G. Mantovani
Researcher at University of Milan
Publications - 361
Citations - 38356
Lorenzo G. Mantovani is an academic researcher from University of Milan. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 51, co-authored 324 publications receiving 26740 citations. Previous affiliations of Lorenzo G. Mantovani include University of Naples Federico II & University of Milano-Bicocca.
Papers
More filters
Journal ArticleDOI
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
Alexander G.G. Turpie,Lorenzo G. Mantovani,Sylvia Haas,Reinhold Kreutz,Danja Monje,Jonas Schneider,Martin van Eickels,Martin Gebel,Walter Ageno +8 more
TL;DR: Patients who switched to rivaroxaban early in the treatment process had a higher frequency of risk factors for bleeding and recurrent VTE than patients treated with rivroxaban; reflected by the higher risk of adverse events in that group during follow-up.
Journal ArticleDOI
Summary report of the First International Conference on inhibitors in haemophilia A.
Sébastien Lacroix-Desmazes,David W Scott,Jenny Goudemand,Marijke van den Berg,Michael Makris,Alice S. van Velzen,Elena Santagostino,David Lillicrap,Frits R. Rosendaal,Anneliese Hilger,Zuben E. Sauna,Johannes Oldenburg,Lorenzo G. Mantovani,M Elisa Mancuso,Craig M. Kessler,Charles R. M. Hay,Paul Knoebl,Giovanni Di Minno,Keith Hoots,Amanda Bok,M. Brooker,Erica Buoso,Pier Mannuccio Mannucci,Flora Peyvandi +23 more
TL;DR: The First International Conference on Inhibitors in Haemophilia A was held on 4–5 March, 2016 and the major theme was the development of factor VIII (FVIII) inhibitors, which occurs in 30–35% of previously untreated children infused with the available commercial products.
Journal ArticleDOI
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study
Paolo Cortesi,I. Olivieri,S De Portu,Carlo Salvarani,Alberto Cauli,Ennio Lubrano,Antonio Spadaro,Fabrizio Cantini,Maria Stefania Cutro,Alessandro Mathieu,Marco Matucci-Cerinic,N. Pappone,Leonardo Punzi,Raffaele Scarpa,Lorenzo G. Mantovani +14 more
TL;DR: In this article, the authors evaluated long-term costs and benefits of TNF inhibitors in psoriatic arthritis patients with inadequate response to conventional treatment with traditional disease-modifying anti-rheumatic drugs (tDMARDs).
Journal ArticleDOI
Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A
Pier Mannuccio Mannucci,Paolo Cortesi,Matteo Nicola Dario Di Minno,Mario Sanò,Lorenzo G. Mantovani,Giovanni Di Minno +5 more
TL;DR: In this article, the authors conducted a combined evaluation of the individual pivotal trials in order to assess between-product differences regarding the reported efficacy results and FVIII consumption, suggesting a different economic impact for the different EHL-rFVIII products in the context of comparable clinical efficacy.
Journal ArticleDOI
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
Sylvia Haas,Gerlind Holberg,Reinhold Kreutz,Michael R. Lassen,Lorenzo G. Mantovani,Verena Haupt,Kai Vogtländer,Alexander G.G. Turpie +7 more
TL;DR: The effectiveness and safety of rivaroxaban in patients undergoing major orthopedic surgery in routine clinical practice were maintained irrespective of timing of the first postoperative dose within 24 hours after surgery, the type of anesthesia, and the additional use of mechanical thromboprophylaxis.